“Venom: The Last Dance” enjoyed another weekend at the top of the box office. The Sony release starring Tom Hardy added $26.1 million in ticket sales, according to studio estimates Sunday.

It was a relatively quiet weekend for North American movie theaters leading up to the presidential election. Charts were dominated by big studio holdovers, like “Venom 3,” “The Wild Robot” and “Smile 2,” while audiences roundly rejected the Tom Hanks, Robin Wright and Robert Zemeckis reunion “Here.” Thirty years after “Forrest Gump,” “Here” opened to only $5 million from 2,647 locations.

“Venom 3” only fell 49% in its second weekend, which is a notably small drop for a superhero film, though it didn’t exactly open like one either. In two weeks, the movie has made over $90 million domestically; The first two opened to over $80 million. Globally, the picture is brighter given that it has already crossed the $300 million threshold.

Meanwhile, Universal and Illumination’s “The Wild Robot” continues to attract moviegoers even six weeks in (and when it’s available by video on demand), placing second with $7.6 million. That’s up 11% from last weekend. The animated charmer has made over $121 million in North America and $269 million worldwide.

“‘The Wild Robot’ has quietly been this absolute juggernaut for the fall season,” said Paul Dergarabedian, the senior media analyst for Comscore. “For that film to see an increase after six weeks is astounding.”

“Smile 2” landed in third place with $6.8 million, helping to push its worldwide total to $109.7 million.

The time-hopping “Here,” a graphic novel that was adapted by “Forrest Gump” screenwriter Eric Roth, was financed by Miramax and distributed by Sony’s TriStar. With a fixed position camera, it takes audiences through the years in one living room. Critics were not on board: In aggregate it has a lousy 36% on Rotten Tomatoes.

“It was a slow weekend anyway, but it didn’t resonate in a way that many thought it might,” Dergarabedian said. “There are a lot of films out there for the audience that ‘Here’ was chasing.”

Despite playing in almost 1,000 more locations, “Here” came in behind Focus Features’ papal thriller “Conclave,” which earned $5.3 million. Playing in 1,796 theaters, “Conclave” dropped only 20% from its debut last weekend and has made $15.2 million so far. Two Indian films also cracked the top 10 in their debuts, “Bhool Bhulaiyaa 3” and “Singham Again.”

Overall box office continues to lag behind 2023 by almost 12%. But holiday moviegoing will likely give the industry an end-of-year boost with titles like “Gladiator II” and “Wicked” on the way.

“In a couple of weeks, it’ll get a lot more competitive,” Dergarabedian said.

Jesse Eisenberg’s film “A Real Pain,” a comedic drama about cousins on a Holocaust tour in Poland, launched in four theaters this weekend in New York and Los Angeles. It made an estimated $240,000, or $60,000 per screen, which is among the top three highest per theater averages of the year. Searchlight Pictures will be expanding the well-reviewed film nationwide in the coming weeks, going wide on Nov. 15 to over 800 theaters.

Even major studios withhold box office numbers occasionally. Earlier this year, Disney did not report on the Daisy Ridley movie .” Results were most notably withheld during the COVID-19 pandemic.

“It’s really up to the distributors,” Dergarabedian said. “Often times the reason that certain movies may not be reported is that there’s a chance that the quality of the movie will be conflated with the box office number.”

Final domestic figures will be released Monday. Estimated ticket sales for Friday through Sunday at U.S. and Canadian theaters, according to Comscore, were:

1. “Venom: The Last Dance,” $26.1 million.

3. “Smile 2,” $6.8 million.

4. “Conclave,” $5.3 million.

5. “Here,” $5 million.

6. “We Live In Time,” $3.5 million.

7. “Terrifier 3,” $3.4 million.

8. “Singham Again,” $2.1 million.

9. “Beetlejuice Beetlejuice,” $2.1 million.

10. “Bhool Bhulaiyaa 3,” $2.1 million.___This story has been corrected to reflect that the seventh film in the top 10 was “Terrifier 3,” not “Terrifier 2.”

Before you make your next trade, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and none of the big name stocks were on the list.

They believe these five stocks are the five best companies for investors to buy now…

See The Five Stocks Here